ArticleThe oncologist2025
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP).
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.Targeted oncology · 2026Review
- Molecular testing, first-line treatment patterns, and survival in metastatic Colombian non-small cell lung cancer: the RECAPC multicenter registry.Frontiers in oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionERBB2-mutant non-small cell lung cancer (NSCLC) represents approximately 1%-4% of all lung adenocarcinomas (LUADs) and has emerged as a distinct molecular subtype. Little is known about NSCLC harboring ERBB2 mutations in Latin America. This study aimed to characterize the real-world clinical characteristics and outcomes of ERBB2-mutant NSCLC in Latin America. MATERIALS AND
methodsPatients with NSCLC harboring ERBB2 mutations detected by next-generation sequencing in tumors or cfDNA were identified in databanks from 3 Latin American countries (Brazil, Colombia, and Mexico). Demographic, clinical, and pathological data were retrieved from electronic medical records.
resultsOf 1245 patients with NSCLC included from January 2015 to September 2022, 35 (2.8%) patients had tumors with ERBB2 mutations. The median age was 60 years (IQR: 49-69), 54.2% of patients were females, 59.4% were never smokers, 51.3% had baseline performance status ECOG 0, 91.5% were diagnosed with stage IV disease, and 29.7% had de novo brain metastasis. The most common ERBB2 mutations were A775_G776insYVMA (40%) and G780_P781dupGSP (20%). The most often co-mutated gene was TP53 (17.1%), and the median tumor mutation burden was 2 mut/Mb (IQR: 1-4). PD-L1 tumor proportion score was ≥50%, 1%-49%, and <1% in 11.4%, 54.2%, and 31.4%, respectively. Regarding treatment patterns, 74.2% of patients received chemotherapy (CT) plus immune checkpoint blockade (ICB) in the first line, and 42.8% received antibody-drug conjugates (ADC) targeting ERBB2 in further lines of therapy, especially trastuzumab emtansine (37.1%) and trastuzumab deruxtecan (5.7%). The median real-world progression-free survival (rwPFS) to the first line was 6.7 months (95%CI, 5.65-8.48). The median real-world overall survival (rwOS) for the entire cohort was 25.9 months (95% CI, 24.4-27.9).
conclusionThis study demonstrated that ERBB2-mutant NSCLC is uncommon among Latin American patients. Despite the vast majority of patients being treated with chemo-immunotherapy (ICB) in the first line, the median rwOS was similar to that reported for non-oncogene-addicted NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.